SUPERNUS PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Allowance for Credit Loss
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2022-05-12
- 2022-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2021-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2020-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
| 2021-12-31 | $0.00 10-K · filed 2022-04-13 |
| 2020-12-31 | $0.00 10-K · filed 2022-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |